CapsoVision is a commercial-stage medical technology company that develops advanced imaging and AI-enabled capsule endoscopy solutions.
For the full year 2025, the company reported revenue of $13.6 million, marking a 15% increase compared to the full year 2024. Fourth quarter 2025 revenue was $3.9 million. The reported net loss per share (EPS)—basic and diluted—for 2025 was $(1.03).
Cash and cash equivalents totaled $10.1 million as of December 31, 2025. Furthermore, the company completed an initial public offering in July 2025, which generated net proceeds of $23.4 million.
This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.
The post CapsoVision Q4 and Full Year 2025 Financial Review first appeared on Alphastreet.
